rs17482753 — LPL LPL G>T (Intergenic Variant)

LPL rs17482753 — An Independent Triglyceride-Lowering Signal at the LPL Locus

Lipoprotein lipase (LPL¹¹ LPL
the enzyme anchored to capillary walls in muscle and adipose tissue that hydrolyzes triglycerides in VLDL and chylomicrons, releasing free fatty acids for energy use or storage) sits at the epicentre of plasma triglyceride regulation. The chromosomal region surrounding LPL on 8p21.3 is one of the most robustly replicated loci in lipid genetics — large meta-analyses consistently rank it among the top determinants of circulating triglyceride levels. rs17482753 is an intergenic variant at position 19,975,135 (GRCh38) within this region. It harbours an independent triglyceride-lowering association that persists after conditioning on the better-known rs12678919 signal, meaning it tags a partially distinct component of the LPL-locus biology.

The T allele at rs17482753 — carried by roughly one in ten people globally — is associated with a favourable metabolic profile: lower fasting triglycerides, higher HDL, and reduced incidence of metabolic syndrome. Carriers of one or two T copies show measurably better triglyceride clearance and lipid metrics than those carrying the common GG genotype.

The Mechanism

As an intergenic variant, rs17482753 does not alter the LPL protein sequence. Its functional role is inferred from its genomic neighbourhood and association patterns. The 8p21.3 LPL region is densely packed with regulatory elements — enhancers, transcription-factor binding sites, and microRNA target sequences — that collectively tune how much LPL enzyme the body produces and how efficiently triglyceride-rich lipoproteins are cleared. The T allele may mark a haplotype that sustains LPL expression through regulatory element variation, or it may tag a splicing or 3' UTR effect in partial linkage with functional variants such as rs13702 (which disrupts a microRNA-410 binding site). The eQTL²² eQTL
Expression quantitative trait locus — a variant that affects gene transcript levels without changing the protein coding sequence landscape of this region is under active investigation.

The downstream metabolic consequence of LPL variation is well understood. Higher effective LPL activity means faster hydrolysis of VLDL³³ VLDL
Very low-density lipoprotein — the liver's primary vehicle for exporting triglycerides into the circulation and chylomicrons⁴⁴ chylomicrons
Dietary fat-carrying particles assembled in the intestine after a meal, the largest triglyceride-rich lipoproteins in circulation. As these particles are processed, they shed phospholipids and apolipoproteins that are transferred to HDL — which is why enhanced LPL-locus activity simultaneously lowers triglycerides and raises HDL cholesterol.

The Evidence

A prospective cohort study by Kwak et al.⁵⁵ Kwak et al.
Kwak J et al. Effect of the Interaction between Seaweed Intake and LPL Polymorphisms on Metabolic Syndrome in Middle-Aged Korean Adults. Nutrients 2023 in the Korean Genome and Epidemiology Study (KoGES) examined rs17482753 in middle-aged Korean adults. Men carrying at least one T allele (GT or TT genotypes) showed statistically significant protective associations across multiple metabolic syndrome components: lower overall metabolic syndrome incidence (HR 0.83, 95% CI 0.71–0.95), lower risk of high triglycerides (HR 0.83, 95% CI 0.70–0.99), lower risk of low HDL cholesterol (HR 0.81, 95% CI 0.69–0.95), and lower blood pressure risk (HR 0.79, 95% CI 0.67–0.93). No significant associations were observed in women, suggesting a sex-specific penetrance pattern consistent with known sex differences in LPL regulation.

The T allele's triglyceride-raising role of the G allele was confirmed in Walia et al.⁶⁶ Walia et al.
Walia GK et al. Evaluation of genetic variants related to lipid levels among the North Indian population. Front Genet 2024, which included rs17482753 in a five-variant weighted genetic risk score for triglycerides and VLDL-C in 2,117 Indian adults. The combined risk score was associated with 36.31 mg/dL higher triglyceride plus VLDL-C levels (β=0.95, p<0.001), placing this variant among the handful of triglyceride- associated SNPs with replicated effects across diverse ancestry groups.

The LPL locus broadly — including rs17482753 — is embedded in the landmark lipid GWAS literature. Teslovich et al.⁷⁷ Teslovich et al.
Teslovich TM et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010 confirmed the LPL region as one of 95 genome-wide-significant lipid loci in over 100,000 participants, and the GLGC 2013 meta-analysis⁸⁸ GLGC 2013 meta-analysis
Willer CJ et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics 2013 in over 188,000 individuals showed that conditional analyses within the LPL region identify multiple independent signals — providing the framework for understanding rs17482753 as a distinct, non-redundant variant relative to rs12678919.

Practical Actions

For the common GG genotype (the population baseline): this variant does not confer the LPL-enhancing haplotype effect associated with the T allele. Dietary triglyceride load — driven primarily by refined carbohydrates and fructose (which stimulate hepatic VLDL-TG synthesis) — is cleared through LPL without the extra regulatory support the T allele may provide. The evidence-based interventions for this genotype are those known to up-regulate LPL expression: omega-3 fatty acids (EPA/DHA), which activate PPAR-α and increase LPL gene transcription, and carbohydrate restriction, which reduces the hepatic VLDL load that LPL must process. A fasting lipid panel to establish a personal triglyceride baseline is the starting point.

For GT and TT carriers: the T allele is associated with a favourable lipid trajectory. Maintaining this advantage by avoiding excess refined carbohydrate and fructose intake prevents overloading the LPL machinery. Periodic lipid monitoring confirms that the genotype-level protection is expressing as favourable triglyceride and HDL levels in the context of the individual's diet.

Interactions

rs17482753 is in partial linkage disequilibrium with other LPL-region variants, notably rs12678919 (a downstream regulatory SNP with its own independent triglyceride-lowering signal) and rs328 (LPL S447X, a coding gain-of-function variant). Conditional analyses in large meta-analyses confirm these represent separate signals — carrying the rs17482753 T allele confers benefit beyond what rs12678919 alone explains.

The LPL locus interacts functionally with the APOC3 cluster (rs2854116, rs2854117): apoC-III is an endogenous inhibitor of LPL activity, and high APOC3 expression can attenuate the benefit of a favourable LPL haplotype. Similarly, APOA5 S19W (rs3135506) reduces LPL activation by apoA-V and has additive triglyceride-raising effects when combined with LPL risk alleles.

The sex-specific pattern observed by Kwak et al. — with significant protective effects in men but not women — is consistent with known hormonal modulation of LPL: oestrogen up-regulates adipose LPL and down-regulates muscle LPL, creating a different background LPL activity level in premenopausal women that may mask or dilute the genotype signal.